Anti-CD19 Antibodies Targeting B-cell Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for B-cell disorders, such as B-cell lymphomas and leukemias, lack effective anti-CD19 antibodies that can specifically target and treat these conditions with minimal side effects.
Innovation Solution
Development of human anti-CD19 antibodies and fragments with specific heavy and light chain variable region sequences that bind to CD19, demonstrating ADCC activity, apoptosis induction, and B-cell proliferation inhibition, which can be used alone or in combination with other treatment modalities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for B-cell disorders are used, then treatment coverage is provided, but specificity and effectiveness against CD19-positive cells is insufficient
Solution Approach 1:
The patent applies local quality by designing antibodies with specific variable regions (VH and VL) that are optimized to bind only to CD19 antigen on B-cell surfaces. The CDR sequences are specifically engineered to recognize CD19 epitopes, providing localized specificity at the molecular binding interface while leaving the rest of the antibody structure compatible with standard immunoglobulin frameworks.
Solution Approach 2:
The patent employs parameter changes by modifying the amino acid sequences in the variable regions of the antibody, particularly the complementarity determining regions (CDRs). Specific substitutions, additions, or deletions in the VH and VL sequences alter the binding affinity and specificity parameters to optimize interaction with CD19 while minimizing off-target effects.
2Measurement precision
If anti-CD19 antibodies are developed to specifically target B-cell malignancies, then treatment precision is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional modules: variable regions (VH and VL) for antigen binding, hinge regions for flexibility, and constant regions for effector functions. This modular structure allows independent optimization of each segment, simplifying the design process while achieving high targeting precision through the variable region sequences.
Solution Approach 2:
The patent employs universality by using standard immunoglobulin constant regions that provide universal effector functions (ADCC, CDC, complement activation) across different antibody variants. This allows the same constant region frameworks to be paired with different variable regions targeting CD19, reducing overall complexity by reusing proven structural elements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively target CD19-positive cells, inducing apoptosis and inhibiting B-cell proliferation, providing a therapeutic option for B-cell lymphomas and leukemias with potential for improved treatment outcomes.
Implementation Method 1
Binding of human CD19 with the anti-CD19 antibodies or fragments thereof described herein may demonstrate ADCC activity, induction of apoptosis and inhibition of B cell proliferation
Data Source
AI summary
Antibodies, fragments thereof and fusion proteins that specifically bind to CD19, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.